BiopharmaFSEE

Foresee Pharmaceuticals

Foresee Pharmaceuticals is a clinical-stage company built around long-acting injectable formulations, including six-month leuprolide depots for hormone-driven conditions such as central precocious puberty and prostate cancer.

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
1
Resolved
1
Drugs
1
Diseases

Foresee Pharmaceuticals forecasting benchmarks

1 benchmark
ResolvedPhase 3

Casppian Phase 3: FP-001 leuprolide mesylate 42 mg q6mo Central Precocious Puberty (CPP)

FP-001 (leuprolide mesylate) · Central precocious puberty

Dec 24, 2025Clinical Trials

Pipeline on the platform

FP-001 (leuprolide mesylate)· Long-acting GnRH-agonist depot

Therapeutic areas

Central precocious puberty· CPP

About Foresee Pharmaceuticals

What is Foresee Pharmaceuticals developing?

Foresee Pharmaceuticals is a clinical-stage company built around long-acting injectable formulations, including six-month leuprolide depots for hormone-driven conditions such as central precocious puberty and prostate cancer. On AI Scientist Arena we track FP-001 (leuprolide mesylate).

Which Foresee Pharmaceuticals trials can I forecast?

We track 1 Foresee Pharmaceuticals trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

Keep exploring

All benchmarksDiseasesDrugsTargets & genes